首页 | 本学科首页   官方微博 | 高级检索  
检索        

长春瑞滨联合卡培他滨治疗转移性乳腺癌的临床研究
引用本文:黄伟炜,郑弘宇,陈强,陈夏,刘健,陈丽敏,陈侃,吴凡.长春瑞滨联合卡培他滨治疗转移性乳腺癌的临床研究[J].海峡药学,2009,21(11):131-133.
作者姓名:黄伟炜  郑弘宇  陈强  陈夏  刘健  陈丽敏  陈侃  吴凡
作者单位:福建省肿瘤医院内科,福州,350014
摘    要:目的观察长春瑞滨联合卡培他滨对紫杉类和/或蒽环类药物治疗后失败的转移性乳腺癌的疗效、安全性。方法39例晚期乳腺癌患者均给予长春瑞滨25mg·m^-2,第一,八天;希罗达口服,950mg·m^-2,1日2次,餐后服用,连续服用14d。21d为1周期,至少完成2周期化疗。每周期评价毒性反应,2周期化疗后评价疗效。结果39例患者有效率达46.2%。无CR病人,PR18例(46.2%),SD13例(33.3%),PD8例(20.5%)。中位肿瘤进展时间(TTP)为6.4个月(1~18个月)。最常见的不良反应为手足综合征、骨髓抑制、神经毒性、胃肠道反应等,多为轻度到中度。结论长春瑞滨联合卡培他滨对紫杉类和/或蒽环类药物治疗后失败的转移性乳腺癌有较好的疗效,毒性可以耐受。

关 键 词:乳腺肿瘤  长春瑞滨  卡培他滨

A clinical study on combination of vinorelbine and capectabine to patients with advanced breast cancer
HUANG Wei-wei,ZHENG Hong-yu,CHEN Qiang,CHEN Xia,LIU Jian,CHEN Li-min,CHEN Kan,WU Fan.A clinical study on combination of vinorelbine and capectabine to patients with advanced breast cancer[J].Strait Pharmaceutical Journal,2009,21(11):131-133.
Authors:HUANG Wei-wei  ZHENG Hong-yu  CHEN Qiang  CHEN Xia  LIU Jian  CHEN Li-min  CHEN Kan  WU Fan
Institution:(Department of Internal Medicine, Fujian Provincial Tumor Hospital, Fuzhou 350014, China)
Abstract:OBJECTIVE To analyze the efficacy and safety of combination of vinorelbine and capecitabine in the treatment for metastatic breast cancer (MBC) patients in whom paclitaxel and/or anthracicline treatment have failed. METHODS Thirty-nine patients with MBC received the combination consisting of vinorelbine 25mg/m^2 on days 1, 8 plus capeeitabine 950mg/m^2 bid given from day 1 to day 14. All patients received chemotherapy every 3 weeks for at least two cycles. Side effects were investigated in each cycle, efficacy was evaluated after two cycles.RESULTS Among these 39 patients, the objective response rate(CR + PR) was 46.2% .The partial response was achieved in 18 patients (46.2%), stable disease in 13 patients (33.3%), and progressive disease was observed in 8 patients (20.5 % ), but no patient achieved complete response. The median time to disease progression(TTP) was 6.4 months(range, 1-18 months). The most frequent clinical adverse events were hand-foot syndrome, neutropenia, neural toxicity, nausea, vomitimg.The majority of events were mild to moderate.CONCLUSION The combination of the vinorelbine and capecitabine is very well tolerated and effective to patients who were resistant to paclitaxel and/or anthracycline.
Keywords:Breast neoplasms  vinorelbine  capecitabine
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号